and EU regulations, provided they are non-therapeutic
These findings were shared on Saturday, June 6 during the symposium, Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)
10.1016/j.phrs.2020.104784 162 WilliamsP
Gala GLP-1 is a verified GLP-1 telehealth provider that scores 3.5/5 in our independent review (Competitive but Mixed)
Through GLP-1R activation, Orforglipron enhances glucose-dependent insulin secretion, improves glycemic control, contributes to lipid homeostasis, and reduces appetite and food intake, supporting its clinical use in obesity and type 2 diabetes [2]